There have been no open-market insider trades at Arbutus Biopharma Corp in the last 12 months.
On the institutional side, 177 funds reported holding ABUS at the end of Q2 2026, and more funds bought than sold. No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | HASTINGS DAVID C | CFO | Sell | 22,183 | $3.28 | $73K | SEC |
| Feb 5, 2025 | Sims Karen | Executive Officer | Sell | 19,348 | $3.28 | $63K | SEC |
| Feb 5, 2025 | McElhaugh Michael J. | CEO | Sell | 23,790 | $3.28 | $78K | SEC |
| Feb 5, 2025 | Naftzger J. Christopher | Executive Officer | Sell | 11,333 | $3.28 | $37K | SEC |
| Aug 16, 2024 | MANCHESTER KEITH S | Director | Sell | 8,846 | $3.69 | $33K | SEC |
| Feb 5, 2024 | Sims Karen | Executive Officer | Sell | 4,358 | $2.31 | $10K | SEC |
| Feb 5, 2024 | HASTINGS DAVID C | CFO | Sell | 9,593 | $2.31 | $22K | SEC |
| Feb 5, 2024 | Sofia Michael J. | Executive Officer | Sell | 9,982 | $2.31 | $23K | SEC |
| Feb 5, 2024 | McElhaugh Michael J. | CEO | Sell | 10,164 | $2.31 | $23K | SEC |
There were no open-market insider trades in ABUS in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
177 investment managers reported holding ABUS in SEC Form 13F filings for Q2 2026.
No congressional trades in ABUS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).